GLP-1 drugs, like semaglutide (Wegovy, Ozempic), show promise in treating Polycystic Ovary Syndrome (PCOS) symptoms. Studies indicate improvements in weight loss, insulin sensitivity, and menstrual regularity in some PCOS patients. While anecdotal evidence and small studies are positive, larger trials are needed to confirm efficacy and address insurance coverage limitations. Current PCOS treatments are largely unchanged for decades, creating a significant unmet need. The drugs' effect appears indirect, improving insulin sensitivity through weight loss, potentially lowering testosterone levels and alleviating associated symptoms. Although effective for some, not all women respond, highlighting the need for further research.

Prepared by Olivia Bennett and reviewed by editorial team.